1. Home
  2. MAMA vs BMEA Comparison

MAMA vs BMEA Comparison

Compare MAMA & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mama's Creations Inc.

MAMA

Mama's Creations Inc.

HOLD

Current Price

$13.93

Market Cap

598.8M

ML Signal

HOLD

Logo Biomea Fusion Inc.

BMEA

Biomea Fusion Inc.

HOLD

Current Price

$1.39

Market Cap

138.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MAMA
BMEA
Founded
2010
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Specialty Foods
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
598.8M
138.1M
IPO Year
2011
2021

Fundamental Metrics

Financial Performance
Metric
MAMA
BMEA
Price
$13.93
$1.39
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
6
Target Price
$19.00
$9.83
AVG Volume (30 Days)
329.8K
1.2M
Earning Date
04-14-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
44.44
69.19
EPS
0.13
N/A
Revenue
$95,420,129.00
N/A
Revenue This Year
$31.09
N/A
Revenue Next Year
$16.12
N/A
P/E Ratio
$111.54
N/A
Revenue Growth
95.54
N/A
52 Week Low
$7.61
$0.87
52 Week High
$17.85
$3.07

Technical Indicators

Market Signals
Indicator
MAMA
BMEA
Relative Strength Index (RSI) 43.05 44.62
Support Level $12.86 $1.23
Resistance Level $14.88 $1.45
Average True Range (ATR) 0.65 0.11
MACD 0.01 0.00
Stochastic Oscillator 29.39 36.08

Price Performance

Historical Comparison
MAMA
BMEA

About MAMA Mama's Creations Inc.

Mama's Creations Inc manufactures and markets fresh deli-prepared foods distributed through grocery, mass, club, and convenience stores across the United States. Its product portfolio includes refrigerated prepared foods such as meatballs, meatloaf, sausage products, and pasta and rice entrees. The products are principally sold to supermarkets, club chains, mass-market retailers, and food distributors. The brand of the company includes Mama's Creations, Mama's Mancini's, The Olive Branch, Creative Salads, and others.

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.

Share on Social Networks: